SiRNA as a tool to improve the treatment of brain diseases: Mechanism, targets and delivery

Ageing Research Reviews

Volumn 21, Issue , 2015, Pages 43-54

  Gomes, Maria João ^a   Martins, Susana ^b   Sarmento, Bruno ^a,c  

^a INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

Author keywords

Blood brain barrier; Brain diseases; Efflux transporters; Nanoparticles; SiRNA

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CELL PENETRATING PEPTIDE; CHITOSAN NANOPARTICLE; COPOLYMER; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; SMALL INTERFERING RNA;

BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BLOOD RETINA BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; BRAIN DISEASE; CANCER THERAPY; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG TRANSPORT; GENE CONTROL; HUMAN; NANOTECHNOLOGY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; ANIMAL; BRAIN DISEASES;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; RNA, SMALL INTERFERING;

EID: 84925762220     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2015.03.001     Document Type: Review

References (118)

1. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007, 59:75-86.
2. Abbott N.J., Patabendige A.A., Dolman D.E., Yusof S.R., Begley D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 2010, 37:13-25.
3. Agarwal S., Hartz A.M.S., Elmquist W.F., Bauer B. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr. Pharm. Des. 2011, 17:2793-2802.
4. Akanuma S., Hosoya K., Ito S., Tachikawa M., Terasaki T., Ohtsuki S. Involvement of multidrug resistance-associated protein 4 in efflux transport of prostaglandin E(2) across mouse blood-brain barrier and its inhibition by intravenous administration of cephalosporins. J. Pharmacol. Exp. Ther. 2010, 333:912-919.
5. Akinc A., Querbes W., De S., Qin J., Frank-Kamenetsky M., Jayaprakash K.N., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 2010, 18:1357-1364.
6. Alam M.I., Beg S., Samad A., Baboota S., Kohli K., Ali J., Ahuja A., Akbar M. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci. 2010, 40:385-403.
7. Armulik A., Genové G., Mäe M., Nisancioglu M.H., Wallgard E., Niaudet C., He L., Norlin J., Lindblom P., Strittmatter K. Pericytes regulate the blood-brain barrier. Nature 2010, 468:557-561.
8. Avendano C., Menendez J. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr. Med. Chem. 2002, 9:159-193.
9. Bauer B., Hartz A.M.S., Fricker G., Miller D.S. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp. Biol. Med. 2005, 230:118-127.
10. Belliveau N.M., Huft J., Lin P.J., Chen S., Leung A.K., Leaver T.J., et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol. Ther. Nucleic Acids 2012, 1:e37.
11. Bhaskar S., Tian F., Stoeger T., Kreyling W., de la Fuente J.M., Grazu V., Borm P., Estrada G., Ntziachristos V., Razansky D. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol. 2010, 7:3.
12. Burgess A., Huang Y., Querbes W., Sah D.W., Hynynen K. Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression. J. Control. Release 2012, 163:125-129.
13. Campbell M., Kiang A.S., Kenna P.F., Kerskens C., Blau C., O'Dwyer L., Tivnan A., Kelly J.A., Brankin B., Farrar G.J., Humphries P. RNAi-mediated reversible opening of the blood-brain barrier. J. Gene Med. 2008, 10:930-947.
14. Cardoso F.L., Brites D., Brito M.A. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res. Rev. 2010, 64:328-363.
15. Chen C., Mei H., Shi W., Deng J., Zhang B., Guo T., Wang H., Hu Y. EGFP-EGF1-conjugated PLGA nanoparticles for targeted delivery of siRNA into injured brain microvascular endothelial cells for efficient RNA interference. PLOS ONE 2013, 8:e60860.
16. Choi Y.K., Kim K.-W. Blood-neural barrier: its diversity and coordinated cell-to-cell communication. Genesis 2008, 10:11.
17. Christophorou M.A., Martin-Zanca D., Soucek L., Lawlor E.R., Brown-Swigart L., Verschuren E.W., Evan G.I. Temporal dissection of p53 function in vitro and in vivo. Nat. Genet. 2005, 37:718-726.
18. De Boer A., Gaillard P. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 2007, 47:323-355.
19. Dorsett Y., Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov. 2004, 3:318-329.
20. Fanning A.S., Anderson J.M. PDZ domains and the formation of protein networks at the plasma membrane. Curr. Top. Microbiol. Immunol. 1998, 228:209-233.
21. Farke C., Viturro E., Meyer H.H., Albrecht C. Identification of the bovine cholesterol efflux regulatory protein ABCA1 and its expression in various tissues. J. Anim. Sci. 2006, 84:2887-2894.
22. Farm P.H. Brain Tumour Research 2013, (17.10.14). http://www.braintumourresearch.org/statistics.
23. Fellner S., Bauer B., Miller D.S., Schaffrik M., Fankhänel M., Spruß T., Bernhardt G., Graeff C., Färber L., Gschaidmeier H., Buschauer A., Fricker G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest. 2002, 110:1309-1318.
24. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
25. Fisher M. Pericyte signaling in the neurovascular unit. Stroke 2009, 40:S13-S15.
26. Fisher M., Abramov M., Van Aerschot A., Xu D., Juliano R.L., Herdewijn P. Inhibition of MDR1 expression with altritol-modified siRNAs. Nucleic Acids Res. 2007, 35:1064-1074.
27. Fountaine T.M., Wood M.J.A., Wade-Martins R. Delivering RNA interference to the mammalian brain. Curr. Gene Ther. 2005, 5:399-410.
28. Fromm M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 2004, 25:423-429.
29. Fuest C., Bankstahl M., Winter P., Helm M., Pekcec A., Potschka H. In vivo down-regulation of mouse brain capillary P-glycoprotein: a preliminary investigation. Neurosci. Lett. 2009, 464:47-51.
30. Fujimura M., Usuki F., Kawamura M., Izumo S. Inhibition of the Rho/ROCK pathway prevents neuronal degeneration in vitro and in vivo following methylmercury exposure. Toxicol. Appl. Pharmacol. 2011, 250:1-9.
31. Gao Y., Liu X.L., Li X.R. Research progress on siRNA delivery with nonviral carriers. Int. J. Nanomed. 2011, 6:1017-1025.
32. Georgieva J.V., Hoekstra D., Zuhorn I.S. Smuggling drugs into the brain: an overview of ligands targeting transcytosis for drug delivery across the blood-brain barrier. Pharmaceutics 2014, 6:557-583.
33. Gilmore J.L., Yi X., Quan L., Kabanov A.V. Novel nanomaterials for clinical neuroscience. J. Neuroimmune Pharmacol. 2008, 3:83-94.
34. Godinho B.M., Ogier J.R., Darcy R., O'Driscoll C.M., Cryan J.F. Self-assembling modified beta-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease. Mol. Pharm. 2013, 10:640-649.
35. Gopalakrishnan S.M., Teusch N., Imhof C., Bakker M.H., Schurdak M., Burns D.J., Warrior U. Role of Rho kinase pathway in chondroitin sulfate proteoglycan-mediated inhibition of neurite outgrowth in PC12 cells. J. Neurosci. Res. 2008, 86:2214-2226.
36. Grimm D., Streetz K.L., Jopling C.L., Storm T.A., Pandey K., Davis C.R., Marion P., Salazar F., Kay M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006, 441:537-541.
37. Hammond S.M., Bernstein E., Beach D., Hannon G.J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000, 404:293-296.
38. Hartmann G., Cheung A., Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther. 2002, 303:273-281.
39. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 2005, 57:173-185.
40. Hermann D.M., Patak P. Bringing drugs into the injured brain and keeping them there. Curr. Pharm. Des. 2011, 17:2748-2749.
41. Herskowitz J.H., Seyfried N.T., Gearing M., Kahn R.A., Peng J., Levey A.I., Lah J.J. Rho kinase II phosphorylation of the lipoprotein receptor LR11/SORLA alters amyloid-beta production. J. Biol. Chem. 2011, 286:6117-6127.
42. Hino T., Yokota T., Ito S., Nishina K., Kang Y.S., Mori S., Hori S., Kanda T., Terasaki T., Mizusawa H. In vivo delivery of small interfering RNA targeting brain capillary endothelial cells. Biochem. Biophys. Res. Commun. 2006, 340:263-267.
43. Hori S., Ohtsuki S., Ichinowatari M., Yokota T., Kanda T., Terasaki T. Selective gene silencing of rat ATP-binding cassette G2 transporter in an in vitro blood-brain barrier model by short interfering RNA. J. Neurochem. 2005, 93:63-71.
44. Huang R.Q., Qu Y.H., Ke W.L., Zhu J.H., Pei Y.Y., Jiang C. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J. 2007, 21:1117-1125.
45. Huang W., Lv M., Gao Z. Polyethylenimine grafted with diblock copolymers of polyethylene glycol and polycaprolactone as siRNA delivery vector. J. Control. Release 2011, 152:e143-e145.
46. Huynh G.H., Deen D.F., Szoka F.C. Barriers to carrier mediated drug and gene delivery to brain tumors. J. Control. Release 2006, 110:236-259.
47. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993, 53:4595-4602.
48. Hynynen K., McDannold N., Vykhodtseva N., Jolesz F.A. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001, 220:640-646.
49. Imai Y., Tsukahara S., Ishikawa E., Tsuruo T., Sugimoto Y. Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn. J. Cancer Res. 2002, 93:231-235.
50. Jayaraman M., Ansell S.M., Mui B.L., Tam Y.K., Chen J., Du X., et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 2012, 51:8529-8533.
51. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (London) 2011, 6:715-728.
52. Kanazawa T., Akiyama F., Kakizaki S., Takashima Y., Seta Y. Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Biomaterials 2013, 34:9220-9226.
53. Kanazawa T., Morisaki K., Suzuki S., Takashima Y. Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles. Mol. Pharm. 2014, 11:1471-1478.
54. Kemper E., van Zandbergen A., Cleypool C., Mos H., Boogerd W., Beijnen J., van Tellingen O. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin. Cancer Res. 2003, 9:2849-2855.
55. Kemper E., Verheij M., Boogerd W., Beijnen J., van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur. J. Cancer 2004, 40:1269-1274.
56. Khatri N., Baradia D., Vhora I., Rathi M., Misra A. Development and characterization of siRNA lipoplexes: effect of different lipids, in vitro evaluation in cancerous cell lines and in vivo toxicity study. AAPS PharmSciTech 2014, 15(6):1630-1643.
57. Kim I., Oh J.L., Ryu Y.S., So J.N., Sessa W.C., et al. Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J. 2002, 16:126-128.
58. Kleemann E., Neu M., Jekel N., Fink L., Schmehl T., Gessler T., Seeger W., Kissel T. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. J. Control. Release 2005, 109:299-316.
59. Kumar P., Wu H., McBride J.L., Jung K.E., Kim M.H., Davidson B.L., Lee S.K., Shankar P., Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 448:39-43.
60. Kuppens I.E., Witteveen E.O., Jewell R.C., Radema S.A., Paul E.M., Mangum S.G., Beijnen J.H., Voest E.E., Schellens J.H. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin. Cancer Res. 2007, 13:3276-3285.
61. Kwon C.H., Luikart B.W., Powell C.M., Zhou J., Matheny S.A., Zhang W., et al. Pten regulates neuronal arborization and social interaction in mice. Neuron 2006, 50:377-388.
62. Lee H.J., Engelhardt B., Lesley J., Bickel U., Pardridge W.M. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther. 2000, 292:1048-1052.
63. Li L., Gu W., Chen J., Chen W., Xu Z.P. Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles. Biomaterials 2014, 35:3331-3339.
64. Lin F., Marchetti S., Pluim D., Iusuf D., Mazzanti R., Schellens J.H., Beijnen J.H., van Tellingen O. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. Clin. Cancer Res. 2013, 19:2084-2095.
65. Liu Q., Hou J., Chen X., Liu G., Zhang D., Sun H., Zhang J. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models. PLOS ONE 2014, 9.
66. Liu Y., Liu Z., Wang Y., Liang Y.R., Wen X., Hu J., Yang X., Liu J., Xiao S., Cheng D. Investigation of the performance of PEG-PEI/ROCK-II-siRNA complexes for Alzheimer's disease in vitro. Brain Res. 2013, 1490:43-51.
67. Lorenz C., Hadwiger P., John M., Vornlocher H.P., Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 2004, 14:4975-4977.
68. Loscher W., Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 2005, 76:22-76.
69. Mackman N. The many faces of tissue factor. J. Thromb. Haemost. 2009, 7:136-139.
70. Mahringer A., Ott M., Reimold I., Reichel V., Fricker G. The ABC of the blood-brain barrier - regulation of drug efflux pumps. Curr. Pharm. Des. 2011, 17:2762-2770.
71. Malhotra M., Tomaro-Duchesneau C., Prakash S. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials 2013, 34:1270-1280.
72. Malmo J., Sandvig A., Varum K.M., Strand S.P. Nanoparticle mediated P-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach. PLOS ONE 2013, 8.
73. Martinez J., Tuschl T. RISC is a 5' phosphomonoester-producing RNA endonuclease. Genes Dev. 2004, 18:975-980.
74. Matter K., Balda M.S. Holey barrier: claudins and the regulation of brain endothelial permeability. J. Cell Biol. 2003, 161:459-460.
75. McRae M., Brouwer K., Kashuba A. Cytokine regulation of P-glycoprotein. Drug Metab. Rev. 2003, 35:19-33.
76. Miller G. Drug targeting. Breaking down barriers. Science 2002, 297:1116-1118.
77. Morrison R.S., Wenzel H.J., Kinoshita Y., Robbins C.A., Done-hower L.A., Schwartzkroin P.A. Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death. J. Neurosci. 1996, 16:1337-1345.
78. Muratovska A., Eccles M.R. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 2004, 558:63-68.
79. Murthy S.K. Nanoparticles in modern medicine: state of the art and future challenges. Int. J. Nanomed. 2007, 2:129-141.
80. Nagpal K., Singh S.K., Mishra D.N. Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB. Expert Opin. Drug Deliv. 2013, 10:927-955.
81. Nascimento A.V., Bousbaa H., Ferreira D., Sarmento B. Non-small cell lung carcinoma: an overview on targeted therapy. Curr. Drug Targets 2014, 15:1-16.
82. Nitta T., Hata M., Gotoh S., et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 2003, 161:653-660.
83. Nori A., Jensen K.D., Tijerina M., Kopecková P., Kopecek J. Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjug. Chem. 2003, 14:44-50.
84. O'Mahony A.M., Godinho B.M., Cryan J.F., O'Driscoll C.M. Non-viral nanosystems for gene and small interfering RNA delivery to the central nervous system: formulating the solution. J. Pharm. Sci. 2013, 102:3469-3484.
85. Pardridge W.M. blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv. 2003, 3:90.
86. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005, 2:3-14.
87. Paturi D.K., Kwatra D., Ananthula H.K., Pal D., Mitra A.K. Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3). Int. J. Pharm. 2010, 384:32-38.
88. Peddada L.Y., Garbuzenko O.B., Devore D.I., Minko T., Roth C.M. Delivery of antisense oligonucleotides using poly(alkylene oxide)-poly(propylacrylic acid) graft copolymers in conjunction with cationic liposomes. J. Control. Release 2014, 194C:103-112.
89. Perez-Carrion M.D., Perez-Martinez F.C., Merino S., Sanchez-Verdu P., Martinez-Hernandez J., Lujan R., Cena V. Dendrimer-mediated siRNA delivery knocks down Beclin 1 and potentiates NMDA-mediated toxicity in rat cortical neurons. J. Neurochem. 2012, 120:259-268.
90. Perez-Martinez F.C., Carrion B., Cena V. The use of nanoparticles for gene therapy in the nervous system. J. Alzheimers Dis. 2012, 31:697-710.
91. Pleban K., Ecker G. Inhibitors of p-glycoprotein - lead identification and optimisation. Mini Rev. Med. Chem. 2005, 5:153-163.
92. Pradhan P., Qin H., Leleux J.A., Gwak D., Sakamaki I., Kwak L.W., Roy K. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Biomaterials 2014, 35:5491-5504.
93. Qu M.H., Zeng R.F., Fang S., Dai Q.S., Li H.P., Long J.T. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int. J. Pharm. 2014, 474:112-122.
94. ResearchAndMarkets Drug delivery technology - revolutionizing CNS therapies. PharmaVis. 2007, 1:7-24.
95. Robillard K.R., Chan G.N., Zhang G., la Porte C., Cameron W., Bendayan R. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract. Antimicrob. Agents Chemother. 2014, 58:1713-1722.
96. Rodriguez-Lebron E., Denovan-Wright E.M., Nash K., Lewin A.S., Mandel R.J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 2005, 12:618-633.
97. Rungta R.L., Choi H.B., Lin P.J., Ko R.W., Ashby D., Nair J., Manoharan M., Cullis P.R., Macvicar B.A. Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain. Mol. Ther. Nucleic Acids 2013, 2:e136.
98. Saint-Pol J., Vandenhaute E., Boucau M.C., Candela P., Dehouck L., Cecchelli R., Dehouck M.P., Fenart L., Gosselet F. Brain pericytes ABCA1 expression mediates cholesterol efflux but not cellular amyloid-beta peptide accumulation. J. Alzheimers Dis. 2014, 30:489-503.
99. Sanchez-Covarrubias L., Slosky L.M., Thompson B.J., Zhang Y., Laracuente M.L., DeMarco K.M., Ronaldson P.T., Davis T.P. P-glycoprotein modulates morphine uptake into the CNS: a role for the non-steroidal anti-inflammatory drug diclofenac. PLOS ONE 2014, 9:e88516.
100. Sauna Z.E., Nandigama K., Ambudkar S.V. Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis: effect of transport substrates and characterization of the post-hydrolysis transition state. J. Biol. Chem. 2004, 279:48855-48864.
101. Schinkel A.H., Wagenaar E., Mol C.A.v.D.L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97:2517-2524.
102. Schlachetzki F., Zhang Y., Boado R.J., Pardridge W.M. Gene therapy of the brain: the trans-vascular approach. Neurology 2004, 62:1275-1281.
103. Sethuraman V.A., Bae Y.H. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J. Control. Release 2007, 118:216-224.
104. Sioud M. Overcoming the challenges of siRNA activation of innate immunity: design better therapeutic siRNAs. Methods Mol. Biol. 2015, 1218:301-319.
105. Steffel J., Luscher T.F., Tanner F.C. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 2006, 113:722-731.
106. Tan H.B., Zhong Y.S., Cheng Y., Shen X. Rho/ROCK pathway and neural regeneration: a potential therapeutic target for central nervous system and optic nerve damage. Int. J. Ophthalmol. 2011, 4:652-657.
107. Turner J.J., Jones S., Fabani M.M., Ivanova G., Arzumanov A.A., Gait M.J. RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells. Mol. Dis. 2007, 38:1-7.
108. Veiseh O., Kievit F.M., Fang C., Mu N., Jana S., Leung M.C., Mok H., Ellenbogen R.G., Park J.O., Zhang M. Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials 2010, 31:8032-8042.
109. Watkins P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 1997, 27:161-170.
110. Weber N.D., Merkel O.M., Kissel T., Munoz-Fernandez M.A. PEGylated poly(ethylene imine) copolymer-delivered siRNA inhibits HIV replication in vitro. J. Control. Release 2012, 157:55-63.
111. Weiss N., Miller F., Cazaubon S., Couraud P.-O. The blood-brain barrier in brain homeostasis and neurological diseases. BBA-Biomembranes 2009, 1788:842-857.
112. Wilhelm I., Fazakas C., Krizbai I.A. In vitro models of the blood-brain barrier. Acta Neurobiol. Exp. 2011, 71:113-128.
113. Xu C.-f., Wang J. Delivery systems for siRNA drug development in cancer therapy. Asian J. Pharm. Sci. 2015, 10:1-12.
114. Yang P., Wen H.Z., Zhang J.H. Expression of a dominant-negative Rho-kinase promotes neurite outgrowth in a micro-environment mimicking injured central nervous system. Acta Pharmacol. Sin. 2010, 31:531-539.
115. Zahraoui A., Louvard D., Galli T. Tight junction, a platform for trafficking and signaling protein complexes. J. Cell Biol. 2000, 151:F31-F36.
116. Zamore P.D., Tuschl T., Sharp P.A., Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21-23 nucleotide intervals. Cell 2000, 101:25-33.
117. Zhu L., Mahato R.I. Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin. Drug Deliv. 2010, 7:1209-1226.
118. Zhu L., Perche F., Wang T., Torchilin V.P. Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials 2014, 35:4213-4222.